First revenue just hit 💪🏻

And Wall Street hasn’t caught up yet...

March 04, 2026

Hey Folks, Jeff Bishop here,

Most tiny biotech stocks are years away from seeing a single dollar in product revenue…

My sights are on one who just crossed that line. 🏁

For the first time in company history, it reported revenue following the commercial launch of its lead therapy…

That launch was only in December, but the company still reported $3.9 million in revenue for the quarter ending December 31.

The company is now in “execution” territory, with two more late-stage therapeutics in the pipeline.

The stock has a history of explosive moves, including a 40%+ intraday jump when I alerted it last March, making it one of the top 10 movers in the entire market.

Since its low last week, the stock has been up double-digits and closed in the green yesterday despite the market turmoil.

Here’s what has my attention right now:

-> The company has officially moved from the development stage to commercial-stage

-> First reported revenue confirms launch traction

-> The company just secured $3.8 million in non-dilutive funding 

through a New Jersey economic development program

The company is now at a stage where development risk starts to come off the table, and revenue multiples start to enter the conversation…

And institutions that wouldn’t touch a pure clinical-stage stock begin paying attention.

I’ve put together a full breakdown, including:

-> The revenue details from the February update

-> Why this launch changes the fundamental story

-> The size of its addressable market

-> Upcoming potential catalysts

-> And the specific technical level I’m watching now

If you’re serious about staying ahead of under-the-radar biotech movers, you need to see this before the open.

This is a company that just proved it can generate revenue, and in this market, that kind of transition can matter a lot.

Take the time to get it on your radar before the opening bell.

I have a feeling this one could get interesting fast.

To Your Success,

DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). Full disclaimer: https://bullseyealerts.com/disclaimer/

SPONSORED CONTENT & COMPENSATION: You should assume we receive compensation for any non-SV purchases through links in this email via affiliate relationships, direct/indirect payments from companies or third parties who may own stock in or have other interests in promoted companies ("Clients"). We may purchase, sell, or hold long or short positions without notice in securities mentioned in this communication.

CLIENT CONTENT: SV is not responsible for any content hosted on Client sites; it is the Client's responsibility to ensure compliance with applicable laws.

NOT INVESTMENT ADVICE: Content is for educational, informational, and advertising purposes only and should NOT be construed as securities-related offers or solicitations. All content, regardless of characterization as "educational," should be considered promotional and subject to disclosed conflicts of interest. Do NOT rely on this as personalized investment advice. SV strongly recommends you consult a licensed or registered professional before making any investment decision.

RESULTS NOT TYPICAL: Past performance, testimonials, and historical results are unverified and NOT indicative of future results. Results presented are NOT guaranteed as TYPICAL. Past newsletters, marketing materials, track records, case studies, and promotional content should NOT be relied upon as indication of future performance. Market conditions, regulatory environments, and individual circumstances vary significantly over time. Actual results will vary widely given factors such as experience, skill, risk mitigation practices, market dynamics and capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.

REGULATORY STATUS: Neither SV nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

HIGH-RISK SECURITIES: Securities discussed may be penny stocks, small-cap stocks, cryptocurrencies, options, or other highly speculative investments subject to extreme price volatility, rapid and substantial price movements, limited liquidity, regulatory changes, and potential total loss of value. Market conditions can change rapidly and unpredictably.

LEGAL: In any legal action arising from or related to SV services or these terms, SV shall be entitled to recover attorneys' fees, costs, and disbursements in addition to any other relief.